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Anti-inflammatory therapy by intravenous delivery of
non-heparan sulfate-binding CXCL12
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ABSTRACT Interaction between chemokines and
heparan sulfate (HS) is essential for leukocyte recruit-
ment during inflammation. Previous studies have shown
that a non-HS-binding mutant form of the inflammatory
chemokine CCL7 can block inflammation produced by
wild-type chemokines. This study examined the anti-in-
flammatory mechanism of a non-HS-binding mutant of
the homeostatic chemokine CXCL12. Initial experiments
demonstrated that mutant CXCL12 was an effective
CXCR4 agonist. However, this mutant chemokine failed
to promote transendothelial migration in vitro and inhib-
ited the haptotactic response to wild-type CCL7, CXCL12,
and CXCL8, and naturally occurring chemoattractants in
synovial fluid from the rheumatoid synovium, including
CCL2, CCL7, and CXCL8. Notably, intravenous adminis-
tration of mutant CXCL12 also inhibited the recruitment
of leukocytes to murine air pouches filled with wild-type
CXCL12. Following intravenous administration, wild-type
CXCL12 was cleared from the circulation rapidly, while
the mutant chemokine persisted for >24 h. Chronic
exposure to mutant CXCL12 in the circulation reduced
leukocyte-surface expression of CXCR4, reduced the
chemotactic response of these cells to CXCL12, and
inhibited normal chemokine-mediated induction of adhe-
sion between the a4b1 integrin, VLA-4, and VCAM-1.
These data demonstrate that systemic administration of
non-HS-binding variants of CXCL12 can mediate a pow-
erful anti-inflammatory effect through chemokine recep-
tor desensitization.—O’Boyle, G., Mellor, P., Kirby, J. A.,
Ali, S. Anti-inflammatory therapy by intravenous delivery
of non-heparan sulfate-binding CXCL12. FASEB J. 23,
3906–3916 (2009). www.fasebj.org
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Chemokines are a family of small (8–10 kDa) pro-
teins that play important roles in both normal homeo-
static processes and the recruitment of inflammatory
leukocytes. Chemokines function through binding and
activating specific members of a family of G-protein-
coupled chemokine receptors (GPCRs). While these
receptors can be stimulated by soluble ligands, it is
clear that chemokines in vivo are largely bound to
heparan sulfate (HS) components of proteoglycans on
cell surfaces and within the extracellular matrix (1).
This binding occurs between cationic consensus hepa-
rin-binding domains in the protein sequence and an-
ionic, sulfated regions in HS (2). Previous studies by
our group and others (3, 4) have shown that specific
mutation to disrupt the heparin-binding domain of the
proinflammatory chemokines CCL5 and CCL7 does
not compromise specific GPCR ligation. However, the
mixture of either of these mutants with wild-type che-
mokines can abrogate the potential of the latter to
induce transendothelial leukocyte migration in vitro
and normal chemokine-mediated inflammation in vivo
(4). Although offering tantalizing potential for devel-
opment of systemic anti-inflammatory therapies (2),
the mechanism by which non-HS-binding chemokines
acts is unclear (5). Interactions with HS are known to
promote oligomerization of certain chemokines (6),
and disruption of this biology has been postulated as a
mechanism for their actions in in vivo models (2).
A number of approaches for manipulation of chemo-
kine biology are currently undergoing investigation
(7), including small-molecule-specific chemokine re-
ceptor antagonists (8), virus-derived chemokine-bind-
ing proteins (9), and nonsignaling mutant chemokine
“cell-jammers” (10). In each case, these strategies are
specific for the blockade of single ligands or receptors.
Given the multiple redundancy within both chemo-
kines and their receptors, it seems likely that a strategy
to simultaneously modulate a number of chemokines
will have a clinical advantage (11); indeed, naturally
occurring chemokine “scavenger” receptors such as D6
and DARC can perform this function in vivo by clear-
ance of groups of chemokines (12). Notably, GPCR
agonists, including the chemokines, can induce both
homologous and heterologous receptor tolerance, sug-
gesting that single agents might negate the potential of
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a cell to respond to multiple chemokines (5). Our
group used this argument to explain the observation
that addition of a non-HS-binding, mutant form of
CCL7 to mixed chemokine populations within murine
air pouches limited the inflammatory action of wild-
type chemokines (4). However, simultaneous introduc-
tion to the air pouch of both mutant and wild-type
chemokines does not allow definition of spatial aspects
of the anti-inflammatory activity.
A more realistic strategy is to study the potential of
systemic administration of non-HS-binding mutant che-
mokines to block site-specific recruitment of immune
cells induced by local administration of wild-type che-
mokines. However, CCL7 is a powerful inflammatory
chemokine, and the non-HS-binding form shares the
potential of the wild-type sequence to interact with
CCR1, CCR2, CCR3, and CCR5, which are expressed in
variable proportions by most leukocytes (13). Systemic
administration of inflammatory chemokines is toler-
ated but can be associated with nonspecific immune
activation and inflammation. Indeed, some direct tissue
damage may be caused through widespread induction
of a respiratory burst in responsive phagocytes (14).
The chemokine CXCL12 is a prototypical HS-binding
chemokine; indeed, the less common CXCL12g isoform
is extended at the carboxyl terminus to include an addi-
tional series of BBxB consensus HS-binding domains that
confer one of the highest measured chemokine affinities
for HS (900 pM; ref. 15). This chemokine directs homeo-
static stem-cell and leukocyte trafficking through the
stimulation of CXCR4; reports (16) suggest that CXCL12
can also play a role in directing the site-specific metastatic
spread of some cancer cells. Under normal conditions,
CXCL12 is expressed by specific tissues, including lung,
liver, and bone marrow (17). The constitutive nature of
the expression of this chemotactic ligand is consistent
with reports that stimulation of CXCR4 generally induces
little toxic respiratory burst activity. Notably, a mutant
CXCL12 sequence has been designed that has minimal
affinity for HS (18).
The current study was designed to define the poten-
tial of the non-HS-binding mutant form of CXCL12
(mtCXCL12) to bind CXCR4 and induce normal signal
transduction. A further series of in vitro experiments
was performed to determine how addition of mtCXCL12
can alter the normal migration of leukocytes across
monolayer endothelium in response to wild-type che-
moattractants. After demonstration of limited toxicity
together with prolonged retention in the circulation,
mtCXCL12 was used in combination with wild-type
CXCL12 to examine the potential for systemic block-
ade of site-specific inflammation in vivo. A final series of
experiments was performed to assess the possibility that
persistence of the mutant ligand induces a state of
chemokine unresponsiveness that results in the failure
of integrin activation following normal leukocyte stim-
ulation by HS-bound, wild-type chemokines at the focus
of developing inflammation.
MATERIALS AND METHODS
Chemokines
Human CXCL12 chemokines were synthesized, purified, and
validated by Albachem (East Lothian, UK). Wild-type CXCL12
contains lysine, histidine, and lysine at sequence positions 24,
25, and 27, respectively; each of these residues was changed to
serine in the mtCXCL12 sequence (18). The mutant sequence is
as follows, with the variant residues underscored: KPVSLSYR-
CPCRFFESHVARANVSSLSILNTPNCALQIVARLKNNNRQVCI-
DPKLKWIQEYLEKALNKRFKM. Human CCL7 and CXCL8
were obtained from R&D Systems (Abingdon, UK).
Chemokine receptor activation assays
Radioligand competition assays were performed as described
previously (4), using Chinese hamster ovary (CHO) cells
stably transfected with CXCR4 by our group (19). Briefly, 2 3
105 CHO-CXCR4 cells were pelleted and resuspended in
binding buffer containing chemokine. A tracer concentration
of 100 pM [125I]CXCL12 in 50 ml was then added, and the
assay was incubated for 2 h on ice with shaking. The cells were
then washed twice with 0.5 M NaCl in binding buffer before
being transferred to fresh tubes for counting using a micro-
beta scintillation counter (LKB Wallac; Perkin Elmer, Cam-
bridge, UK). Gai activation, calcium flux, pAKT, and pERK
assays were performed as described previously (20).
Chemotaxis assays
Peripheral blood mononuclear cells (PBMCs) were extracted
from venous blood taken from healthy volunteers. Following
heparinization, blood was diluted in an equal volume of
serum-free RPMI and subjected to density gradient centrifu-
gation using Ficoll-Paque density gradient medium (specific
gravity 1.07760.001g/ml; Amersham Pharmacia, Little Chal-
font, UK). The interfacial layer was harvested and washed by
centrifugation. The human endothelial cell hybridoma
EAhy926 was cultured as described previously (21).
The chemotactic potential of leukocytes was assessed using
a 3-mm Transwell filter system developed using polyethylene
terepthalate chemotaxis filters (Falcon; Fahrenheit Labora-
tory Supplies, Rotherham, UK) and corresponding 24-well
companion plates. In some cases, transendothelial chemo-
taxis was assessed by first culturing 5 3 104 EAhy926 cells on
the filter for 72 h before the migration assay. PBMCs
(23105)were placed in upper chamber of a 3-mm filter,
whereas the lower chamber contained serum-free RPMI sup-
plemented with chemokine. A 1:10 dilution of synovial fluid
drained from the knee of a patient with rheumatoid arthritis
was used in transendothelial chemotaxis assays, as described
previously (4). To assess the chemotactic factors present in
synovial fluid, a 1:10 dilution was analyzed using a chemokine
antibody array (Raybiotech, Norcross, GA, USA), according
to the manufacturer’s instructions.
The assay was incubated for 90 min at 37°C before removal
of excess cells and medium from both chambers. The upper
surface of the filter was gently swabbed to remove nonmigrat-
ing cells before fixation in 100% ice-cold methanol for 1 h.
Each filter was then stained using an a-napthyl acetate
esterase staining kit (Sigma, Poole, UK). Finally, the filters
were dehydrated and mounted. High power microscopy
(3400) was used to count migrant cells in 9 randomly chosen
fields per labeled filter. To assess migration of nonadherent
cells (typically lymphocytes), the medium from the lower
chamber was collected, the cells were pelleted by centrifuga-
tion, and counting was performed by flow cytometry using
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Flow-Count beads (Becton-Dickinson, Cowley, UK). Chemo-
tactic indexes were normalized to express the migration
results as a percentage of the response to wild-type CXCL12.
Partitioning of chemokine in this assay was examined by
ELISA, as described previously (22). Samples were taken
above and below the chemotaxis filter at intervals up to 90
min. Different plates and filters were used for each time point
to minimize disruption to any gradient during sampling. Goat
anti-human CXCR4 antibodies, anti-goat biotin conjugated
secondary antibodies, and streptavidin-horseradish perioxi-
dase were used to perform the ELISA (R&D Systems). To
examine the distribution of chemokine on the endothelium, the
filter was fixed in methanol, and the apical surface of the filter
was stained for CXCL12 using the same reagents as above and
streptavidin-FITC for analysis by confocal microscopy with a
DAPI nuclear counterstain. Confocal sensitivity was adjusted
such that no signal was seen in filters incubated with secondary
anti-goat-biotin and tertiary streptavidin-FITC reagents.
Leukocyte recruitment to murine air pouches
Eight-week-old female BALB/c mice (Charles River, Margate,
UK) were used for generation of air pouches as described
previously (4) in full compliance with UK Home Office
regulations for animal experimentation. Briefly, air pouches
were induced by injecting 3 ml of sterile air subcutaneously
into the back of each animal, followed by 1 ml of air on 3
further occasions (d 2, 4, and 5, respectively); this produced
stable fluid-filled pouches. On d 6, each pouch was injected
with 1 ml of PBS containing either 10 mg of wild-type
CXCL12, mtCXCL12, or a combination of 5 mg of both
chemokine sequences. Age- and sex-matched control mice
were injected with PBS alone.
After 24 h, recruited cells were recovered by gently lavaging
the pouch twice with 0.75 ml of PBS containing 1 mM EDTA.
The exudates were centrifuged at 500 g for 5 min, and the
supernatants were removed. The cell pellets were resus-
pended in 1 ml of PBS, and 200 ml of each cell suspension was
then smeared by cytocentrifugation (Shandon, Runcorn, UK)
and stained with Diff Quick (Sigma) for differential cell
counting, 33/mouse, with 9 fields/cytospin counted. In all
cases, groups of 5 animals were examined, and samples were
counted in a masked procedure by 2 separate investigators.
Splenocytes were isolated by trituration of splenic tissue
before filtration through a 70-mm filter. Leukocytes were then
purified by density gradient centrifugation using Histopaque
1083 (Sigma).
Intravenous administration of chemokine
An additional series of air-pouch experiments was performed to
examine how intravenous administration of chemokine modu-
lated immune cell recruitment to the air pouches. Air pouches
were generated as above, and 20 mg of wild-type CXCL12 or
mtCXCL12 was injected into the tail vein immediately before
instillation of chemokine into the air pouch. Twenty micro-
grams was injected to approximate the chemokine concentra-
tion within the air pouch (10 mg/ml). To assess the clearance of
chemokine, 40 ml of blood was collected from each mouse for
up to 24 h following administration. Following 1 h of clotting,
the serum was harvested by centrifugation, and the CXCL12-
specific ELISA was performed as above.
To test the ability of serum from these mice to modulate
CXCR4 expression, MOLT-16 T-cells were incubated with a
1:1 dilution of serum from each group of animals. After 90
min, CXCR4 expression was measured by flow cytometry. As a
negative control, cells were incubated in the serum of mice that
had only received PBS IV. For a positive control, 10 nM of
wild-type CXCL12 was used to supplement serum from PBS
mice.
To examine the oxidative burst activity of whole blood, a
Burst Test kit (Orpegen Pharma, Heidelberg, Germany) was
used. A volume of 100 ml of heparinized mouse blood was
stimulated with either chemokine, 50 mM fMLP, or 2 3 107
opsonized Escherichia coli for 10 min at 37°C. On stimulation,
leukocyte production of reactive oxygen metabolites, such as
superoxide anion, hydrogen peroxide, and hypochlorous acid,
was monitored by the addition and oxidation of dihydrorho-
damine 123 to rhodamine 123 and measured by flow cytometry.
Integrin activation assay
Changes in integrin affinity for the ligand VCAM-1 were
measured using a VCAM-1.Fc fusion protein-binding assay
that was modified from a previous report for use with
MOLT-16 T cells (23). Briefly, 10 ml of 400 mg/ml VCAM-1.Fc
fusion protein (R&D Systems) was added to 8 3 105 cells in 20
ml of PBS containing 0.5% BSA at 37°C; in some cases the fusion
protein was cross-linked with a FITC-conjugated anti-Fc anti-
body for 30 min to form a fluorescent oligomeric immune
complex before addition to the cells. Then, 10 nM chemo-
kine or, for positive control, either 1 mM Mn21 or 10 nM
PMA was added, and the cells were fixed after appropriate
incubation periods by addition of 500 ml prewarmed 4%
paraformaldehyde in PBS. After fixation for 5 min, 3 ml
ice-cold PBS was added. If necessary, the cells were then
washed and stained with a FITC-conjugated anti-Fc secondary
antibody (Sigma) before analysis by immunofluorescence
flow cytometry.
Statistical analyses
All results are expressed as means 6 se of replicate samples.
The significance of changes was assessed by the application of
an ANOVA with Tukey’s posttest. All data were analyzed using
Prism 3 software (GraphPad, San Diego, CA, USA).
RESULTS
HS affinity does not alter agonist activity
An initial series of experiments was performed to study
the agonist activity of mtCXCL12. Heparin-Sepharose
chromatography demonstrated that mtCXCL12 had a
lower affinity than the wild-type chemokine for hepa-
rin, being eluted from heparin-Sepharose columns by
0.55 and 0.8 M NaCl, respectively (not shown).
Radioligand-binding experiments indicated that
mtCXCL12 had an affinity for CXCR4 that was identical
to the wild-type sequence (Fig. 1A). The trend in compe-
tition was similar for the wild-type and mtCXCL12,
indicating similar affinities for CXCR4, with IC50 values
of 6.3 nM (95% confidence interval between 4.8 and
8.2 nM) and 7.8 nM (95% confidence interval between
4.8 and 12.6 nM), respectively. Cell-activation assays
demonstrated that mtCXCL12 was able to fully activate
the receptor and elicit complete signal transduction,
including adenylate cyclase inhibition (Fig. 1B), gener-
ation of a cytoplasmic calcium flux (Fig. 1C), and
phosphorylation of AKT (Fig. 1D) and ERK (Fig. 1E).
Both wild-type and mtCXCL12 were able to induce
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migration of PBMCs in a GAG-independent transfilter
chemotaxis assay (Fig. 1F). Together these data dem-
onstrate that mtCXCL12 does not differ from wild-type
CXCL12 in its ability to activate CXCR4 and subsequent
chemokine receptor signal transduction pathways.
Non-HS-binding receptor agonist has a dominant
inhibitory effect on transendothelial migration
Wild-type CXCL12 elicited significant migration of
PBMCs across an endothelial monolayer (P,0.001),
whereas mtCXCL12 was unable to induce the migra-
tion of either adherent monocytes or nonadherent
lymphocytes across a monolayer of endothelial cells
(Fig. 2A). Further experiments demonstrated the po-
tential of mtCXCL12 to antagonize the normal re-
sponse to the wild-type chemokine. When used at
equimolar concentrations, a mixture of 5 nM wild-type
CXCL12 and 5 nM mtCXCL12 did not elicit any
significant migration of nonadherent cells across the
endothelial monolayer (Fig. 2B); a similar result was
observed when 2.5 nM mtCXCL12 was mixed with 7.5
nM wild-type CXCL12 (P,0.05, compared with wild-
type CXCL12 alone).
A 1:10 dilution of synovial fluid drained from the
knee of a patient with rheumatoid arthritis provides a
broad-spectrum stimulus in leukocyte chemotaxis as-
says (4). The chemokines present in synovial fluid were
examined by antibody array, with chemokines includ-
ing CCL7, CCL8, and CXCL8 detectable (Fig. 3A).
These are consistent with a number of published stud-
ies describing the chemokine milieu within the in-
flamed synovium (24). Addition of synovial fluid to the
lower chamber of a transendothelial chemotaxis assay
induced a significant migration of PBMCs through the
filter (Fig. 3B). However, addition of either 10 or 1 nM
concentrations of mtCXCL12 to the diluted synovial
fluid in the lower chamber reduced the response to
background levels; addition of wild-type CXCL12 did
not significantly diminish the response to this synovial
fluid. Further experiments demonstrated a significant
reduction in transendothelial PBMC migration toward
either CCL7 or CXCL8 following the addition of
mtCXCL12 to the lower chamber (in both cases,
P,0.05); wild-type CXCL12 did not inhibit migration
toward either CCL7 or CXCL8 (P.0.05; Fig. 3C).
Non-HS-binding CXCL12 does not partition to the
endothelium
There was no difference between the wild-type and
mtCXCL12 in their capacity to diffuse across a Trans-
well filter (Fig. 4A). When a monolayer of endothelial
cells was cultured on the filter, little wild-type CXCL12
was found in free solution on the apical surface at time
points up to 90 min. In contrast, significant levels of
Figure 1. Receptor activation by wild-type and mtCXCL12 is identical. A) Radioligand competition binding assays were
performed. Squares show data using wild-type (wt) CXCL12; circles show data using mtCXCL12. B) Chemokine-mediated Gai
activation was demonstrated using an adenylate cyclase inhibition assay with PBMCs stimulated with 100 mM forskolin alone or
forskolin plus 10 nM wild-type or mtCXCL12. C) Representative changes in intracellular Ca21 following 10 nM wild-type
CXCL12 (solid line) and mtCXCL12 (dashed line) stimulation. Second peak is the result of positive control treatment with
ionomycin. D) Serum-starved PBMCs were treated with 10 nM chemokine for 5 min, cell lysates were prepared, and
phosphorylation of Akt was measured by ELISA. E) Analysis of ERK1/2 activation in serum-starved PBMCs treated with 10 nM
wild-type or mtCXCL12 for 2 min. Lysates were fractionated by SDS-PAGE, followed by Western blotting with pERK-specific
antibodies (top blot) and then stripped and reprobed for ERK1 (bottom blot). F) Migration of PMBCs across filters in response
to 10 nM wild-type or mtCXCL12; data are expressed as chemotactic indices after normalization to the maximal response. In
all cases, results represent 1 of 3 independent experiments; data are means 6 se.
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mtCXCL12 were found in free solution (P,0.05).
Immunofluorescent staining and confocal microscopy
were employed to examine the presentation of
CXCL12 in this assay. The mtCXCL12 was not bound to
the endothelial surface; however, apical presentation of
the wild-type chemokine was observed (Fig. 4B).
Non-HS-binding CXCL12 can limit inflammation in vivo
A murine model of inflammation was used to assess the
in vivo modulation of CXCL12 activity by mutation of
the GAG-binding domain. Air pouches were formed by
subcutaneous injection of air into the back of mice;
these pouches develop a lining that resembles the
synovial membrane (25). Injection of 10 mg of wild-type
CXCL12 into air pouches induced significant recruit-
ment of lymphocytes (P,0.05) and mononuclear
phagocytes (P,0.01) after 24 h (Fig. 5). At this time,
more than twice as many lymphocytes were recruited to
the air pouches by wild-type CXCL12 than by PBS,
demonstrating that this homeostatic chemokine can
induce significant inflammation in this model. The
recruitment of cells in response to mtCXCL12 was not
significantly greater than that produced by injection of
PBS (P.0.05); the failure of the mutant sequence to
recruit leukocytes in vivo was apparent for all the
leukocyte populations enumerated after differential
staining. Notably, injection of a 1:1 mixture of wild-type
CXCL12 and mtCXCL12 elicited no more lymphocyte
infiltration than was observed with PBS alone (P.0.05);
this effect extended to all leukocyte subpopulations
(Fig. 5).
Modulation of inflammatory recruitment by
intravenous chemokine
The ability of intrapouch mtCXCL12 to antagonize
leukocyte migration into the air pouch is consistent
with the results from previous studies in which the
non-HS-binding mutant chemokine CCL7 was mixed
with the wild-type chemokine at a single site (4). In the
current study, a further series of experiments was
performed to assess the effect of intravenous mtCXCL12 on
the intra-air pouch inflammatory response.
A series of experiments contrasted the effect of
intravenous chemokine on leukocyte recruitment to
wild-type CXCL12-filled air pouches (Fig. 6). Positive
Figure 2. mtCXCL12 can antagonize the response to wild-type
CXCL12 in vitro. A) PBMCs were stimulated to migrate across
monolayers of endothelial cells toward 10 nM wild-type (wt)
or mtCXCL12. Data are expressed as chemotactic indices
after normalization to the maximal response. B) Transendo-
thelial migration assays were performed using a range of
concentrations of mixed wild-type and mtCXCL12; nonad-
herent cells in the lower chamber were counted, and data are
expressed as chemotactic indices. In both cases, results rep-
resent independent experiments; data are means 6 se.
Figure 3. mtCXCL12 can antagonize a range of chemotactic factors. PBMCs were stimulated to migrate across monolayers of
endothelial cells toward a 1:10 dilution of synovial fluid (SF) drained from the knee of a patient with rheumatoid arthritis.
A) Chemotactic factors present in SF were examined by membrane array, and densitometric analysis was performed to examine
the relative abundance of a range of chemokines. B) Varying concentrations of wild-type or mtCXCL12 were added to the lower
chamber in combination with the diluted SF. Results represent 1 of 3 experiments performed using SF from different donors.
C) Wild-type or mtCXCL12 (2.5 nM) was added to the lower chamber in combination with 7.5 nM CXCL8 or CCL7. Data are
mean 6 se chemotactic indices for mononuclear cells.
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and negative control groups, with intravenous PBS and
intrapouch PBS, or intravenous PBS and intrapouch
wild-type CXCL12, showed levels of infiltrating leuko-
cytes that were similar to those in earlier experiments
(Fig. 5). Interestingly, intravenous administration of
wild-type CXCL12 promoted an increased infiltration
of PBS-filled air pouches. This increase in infiltration of
PBS-filled air pouches was not observed following intra-
venous administration of mtCXCL12; indeed, in these
animals the level of lymphocyte infiltration of PBS-filled
air pouches was slightly lower than that observed in
animals that received intravenous PBS (P,0.05).
Notably, intravenous administration of mtCXCL12 to
animals with wild-type CXCL12 in their air pouches
resulted in a significant decrease in the number of both
lymphocytes and mononuclear phagocytes entering the
Control staining
Figure 4. mtCXCL12 is not presented by the apical surface of endothelium. A) Soluble chemokine levels were measured by
ELISA for up to 90 min following addition to the lower chamber of a chemotaxis assay with and without an endothelial
monolayer. Black bars, wild-type CXCL12 across a filter; open bars, mtCXCL12 across a filter; hatched bars, wild-type CXCL12
across a monolayer; cross-hatched bars, sampling from mtCXCL12 across a monolayer. Data are means 6 se. B) Partitioning of
chemokine on the apical surface of the endothelium was examined by confocal microscopy. CXCL12 is labeled green with blue
DAPI nuclear counterstain. Scale bars 5 25 mm.
Figure 5. mtCXCL12 can antagonize the re-
sponse to wild-type CXCL12 in vivo. Compari-
son of the potential of wild-type and mtCXCL12
to recruit cells using a murine air pouch model.
Air pouches were injected with 10 mg of wild-
type (wt) or mt CXCL12, or a 1:1 mixture of
both wild-type and mtCXCL12 (5 mg of each
protein), or PBS; in each case, n 5 5. Number
of recruited lymphocytes and mononuclear
phagocytes was evaluated 24 h after administra-
tion of the chemokines. Representative results
are shown from 1 of 3 separate experiments;
data are means 6 se.
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pouch compared with groups that received only intra-
venous PBS (in both cases, P,0.01). In contrast, intra-
venous administration of wild-type CXCL12 slightly
increased the mean number of cells infiltrating air
pouches filled with wild-type CXCL12. Together, these
data suggest that systemic administration of non-HS-
binding CXCL12 is able to inhibit localized, CXCL12-
mediated inflammation within the air pouch.
To assess the kinetics of chemokine clearance from the
blood after intravenous administration of the wild-type
and mutant sequences, 40-ml blood samples were taken
from the tail vein for up to 24 h. The serum was collected,
and the CXCL12 levels were analyzed by ELISA; wild-type
CXCL12 was cleared within 1 h of injection (Fig. 7A),
whereas mtCXCL12 remained above detectable levels in
the serum for up to 24 h after injection.
To identify a possible mechanism for the anti-inflam-
matory activity of the mtCXCL12 sequence, splenocytes
were isolated from chemokine-treated animals and ana-
lyzed by immunofluorescence flow cytometry to quantify
cell surface expression of the CXCL12 receptor CXCR4
(Fig. 7B). Twenty-four hours following intravenous ad-
ministration of 20 mg mtCXCL12, there was a significant
reduction in the expression of cell-surface, immunoreac-
tive CXCR4 (P,0.01). A small reduction in CXCR4 was
also seen at this time after administration of 20 mg
wild-type CXCL12, although this did not reach statistical
significance (P50.08). Splenocytes from mice that re-
ceived intravenous mtCXCL12 were isolated after 24 h
and applied to standard chemotaxis assays to assess their
potential to migrate toward wild-type CXCL12 and were
less responsive to CXCL12 than splenocytes from PBS
control animals (data not shown). To test whether the
residual mtCXCL12 as measured in Fig. 7A was sufficient
to influence receptor expression, MOLT-16 T cells were
incubated for 90 min with serum from each group. A
significant reduction in surface CXCR4 was seen follow-
ing incubation with serum from mtCXCL12-treated mice
compared with those incubated with serum from wild-type
CXCL12- or PBS-treated mice (Fig. 7C; P,0.05).
To examine possible side effects of intravenous chemo-
kine delivery, oxidative burst activity of murine peripheral
leukocytes was examined. There was no significant burst
response following treatment with 10 mg/ml of either
wild-type or mtCXCL12; this dose corresponds to that
initially delivered by injection. In contrast to this, the
proinflammatory chemokine CCL7 did elicit a mild flux
in 4% of cells, although this was significantly less than that
seen in samples stimulated with opsonized E. coli (Fig. 7D;
P,0.05). No IFN-g release was detectable from peripheral
murine leukocytes up to 6 h following treatment with 10
mg/ml CXCL12 (data not shown).
Integrin activation is perturbed by chronic chemokine
exposure
A series of experiments was performed to assess the effect
that chronic (6 h) exposure of leukocytes to mtCXCL12
in the circulation would have on CXCL12-mediated acti-
vation of the a4b1 integrin VLA4. Activation of the
adhesive potential of this integrin has previously been
investigated using a immunofluorescence flow cytometric
assay to measure the binding of a soluble human adhe-
sion molecule.Fc fusion proteins to appropriate immune
cells (23). In this study, the VLA-4- and CXCR4-expressing
MOLT-16 T cell line (26) was stimulated with wild-type
CXCL12 and within 1 min showed a transient increase in
the potential to bind VCAM-1.Fc (Fig. 8A). There was no
difference between the potential of wild-type CXCL12
and mtCXCL12 to activate this integrin (Fig. 8B), with
both chemokines producing an increase in adhesion of
comparable magnitude to that induced by the positive
control reagent (1 mM MnCl2). In further experiments,
T cells that encountered CXCL12 for the first time were
contrasted with those that had been washed by centrifu-
gation after chronic exposure for 6 h to 10 nM of
wild-type or mtCXCL12; chronic exposure was found to
abolish the potential of further exposure to wild-type
CXCL12 to enhance the adhesion of either monomeric
or oligomeric VCAM-1.Fc fusion proteins (Fig. 8C, D,
respectively). Notably, restimulation of cells that had been
previously exposed transiently to 10 nM of wild-type or
mtCXCL12 for 20 min before washing and resting for 5 h
and 40 min bound the VCAM-1.Fc fusion protein as well
as T cells acutely stimulated with CXCL12 (Fig. 8C).
Figure 6. Intravenous administration of mtCXCL12 modu-
lates inflammation. Effect of systemic administration of wild-
type or mtCXCL12 on recruitment of leukocytes to murine
air pouches. Air pouches were injected with 10 mg of wild-type
or mtCXCL12 or PBS, and 20 mg of wild-type or mtCXCL12
or PBS was simultaneously given intravenously; in each case,
n 5 5. After 24 h, the cells recruited to the pouch were
quantified. Representative results are shown from 1 of 3
separate experiments; data are means 6 se.
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DISCUSSION
CXCL12 is a well-studied chemokine that is expressed
constitutively by a number of tissues to maintain ho-
meostatic body functions (27). A previous study of the
interaction between this chemokine and glycosamino-
glycans led to the development of a mutant sequence
variant with reduced affinity for HS (18). Non-HS-
binding variants of the inflammatory chemokines CCL5
(2) and CCL7 (4) are known to have immunoregula-
tory properties. The current study was designed to
assess the potential of the non-HS-binding form of the
homeostatic chemokine CXCL12 to modulate normal
chemokine-mediated inflammation.
Figure 7. mtCXCL12 persists in the circulation and affects both CXCR4
expression and function. A) After intravenous administration of 20 mg of
wild-type (closed bars) or mtCXCL12 (open bars), blood was sampled for up to
24 h for analysis of chemokine concentration by ELISA; broken line is the
background seen in PBS treated mice (n55). B) After 24 h, splenic mononu-
clear cells were purified from each group of animals and from a PBS-treated
control group (n55) and labeled with anti-CXCR4. Median immunofluores-
cence values are shown; broken line indicates background isotype control
fluorescence. C) CXCR4 staining performed on MOLT-16 T cells 90 min
following incubation with serum from mice treated with PBS, wild-type, or
mtCXCL12. Serum from the PBS-treated group was supplemented with 10 nM
CXCL12 as a positive control. Median immunofluorescence values are shown;
broken line indicates background isotype control fluorescence. D) Oxidative burst activity of whole mouse blood was
examined by a dihydrorhodamine 123 assay following 10 min stimulation with 10 mg/ml chemokine, 50 mM fMLP or 2 3
107 opsonised E. coli for 10 min at 37°C. Data are means 6 se.
Figure 8. Chronic exposure to CXCL12 prevents chemokine-mediated,
proadhesive activation of the a4b1 integrin. A flow cytometric assay was used
to measure changes in the binding of VCAM-1.Fc fusion protein following
CXCL12 stimulation of a T-cell line. A) Treatment with 10 nM wild-type
CXCL12 rapidly and transiently increases the binding of monomeric VCAM-
1.Fc. B) T-cell line was treated for 1 min with 10 nM wild-type (wt) or
mtCXCL12 before analysis of monomeric VCAM-1.Fc binding; stimulation
with PBS or Mn21 were used for negative and positive control respectively. C) T-cell
line was untreated (acute), treated with 10 nM wt or mt CXCL12 for 6 h
(chronic), treated with wild-type or mtCXCL12 for 20 min, then washed and
cultured with no ligand for 5 h 40 min (transient). Each of the cell samples
was then washed and stimulated with 10 nM wild-type CXCL12 for 1 min
before measurement of monomeric VCAM-1.Fc binding; stimulation with PBS or Mn21 were used for negative and positive
control respectively. D) Assay was performed as in C except antibody-crosslinked, oligomeric VCAM-1.Fc was used to
determine integrin avidity changes; in this case PMA stimulation was used for positive control. In all cases, results represent
1 of 3 independent experiments; data are means 6 se.
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No significant difference was found between wild-
type CXCL12 and mtCXCL12 with respect to their
receptor affinities or their abilities to induce G-protein
coupling, cytoplasmic Ca21 fluxes, Akt activation, or
ERK activation. Furthermore, both chemokine se-
quences induced similar leukocyte migration in a free-
diffusion model of chemotaxis. However, unlike wild-
type CXCL12, the mtCXCL12 was unable to stimulate
the migration of either mononuclear phagocytes or
lymphocytes across a monolayer of endothelial cells.
Notably, the mtCXCL12 variant had a powerful inhib-
itory effect on leukocyte migration induced by wild-type
CXCL12 or the mixture of chemokines (24) and other
chemoattractant factors (28) present in synovial fluid
drained from the rheumatoid synovium. This is consis-
tent with results that have been reported for a non-HS-
binding form of the inflammatory chemokine CCL7
(4) and may be a consequence of heterologous recep-
tor desenstization (5, 29). To investigate this possibility,
wild-type or mtCXCL12 were separately mixed with
mononuclear cell prototypical CC and CXC chemo-
kines (30), CCL7 and CXCL8, in the lower chamber of
transendothelial chemotaxis assays. It was found that
the normal chemotactic response was inhibited by
mtCXCL12 but not by the wild-type chemokine. These
data suggest that treatment with mtCXCL12 induces
desensitization of receptors other than CXCR4; this
phenomenon is not fully understood but may be of
significant value for the development of anti-inflamma-
tory therapies (5, 31).
Experiments were performed to examine the differ-
ences between the wild-type and mtCXCL12 in the
in vitro chemotaxis assays. Both chemokines diffused
equally across a bare filter; however, only the wild-type
chemokine was efficiently sequestered and presented
by the apical surface of the endothelial monolayer.
After 90 min, significant levels of mtCXCL12 were
observed in the medium above the endothelial mono-
layer. This suggests a mechanism for our earlier obser-
vations and is consistent with our earlier report that
significant levels of addition of a chemokine to the
upper chamber of this assay can result in receptor cross
desensitization and the importance of apical presenta-
tion (22, 32).
These experimental observations were extended to a
murine model. The air-pouch system has been used for
.20 yr to assess inflammation and provides a well-
established method for studying chemokine-mediated
leukocyte migration (4, 33). This model was used for an
in vivo chemotaxis assay in which introduction of
wild-type CXCL12 to air pouches was found to elicit
significant lymphocyte and mononuclear phagocyte
recruitment. These results are consistent with a previ-
ous report (34) that subcutaneous injection of CXCL12
elicited specific infiltration by mononuclear leukocytes;
,1% of the infiltrating cells were neutrophils. Notably,
the presence of mtCXCL12 within the pouches did not
induce leukocyte recruitment. Furthermore, mixture of
wild-type CXCL12 with the non-HS-binding mutant
sequence resulted in abrogation of the chemotactic
potential of the wild-type chemokine; a similar obser-
vation was made with the in vitro chemotaxis assay.
A series of experiments was performed to assess the
potential of wild-type CXCL12 and mtCXCL12 for
systemic application. Initial observations demonstrated
that wild-type CXCL12 was effectively cleared from
murine blood within 1 h of intravenous administration.
This rapid clearance is consistent with the reported
25.8 min half-life of CXCL12 in the circulation of rats
(35) and may reflect normal sequestration to appropri-
ately sulfated domains in HS on the apical surface of
endothelial cells (22); such sequestered CXCL12 can
be remobilized and maintained in the blood by injec-
tion of soluble heparin-like molecules (36). The failure
of mtCXCL12 to bind intravascular HS proteoglycans
provides a likely explanation for the retention of 60%
of this variant chemokine in the blood of treated mice
after 6 h. Significant levels of the mtCXCL12 were
detectable up to 24 h following intravenous administra-
tion. This observation is consistent with the duration of
receptor internalization and leukocyte desensitization
toward CXCL12 that we observed in splenocytes from
these animals. Notably, the residual mtCXC12 present
in serum taken 24 h following intravenous administra-
tion was sufficient to cause internalization of CXCR4
when applied to a T-cell line. The level of CXCR4
internalization observed was similar to that observed
when fresh CXCL12 was applied.
No obvious toxic effects were observed after intrave-
nous administration of 20 mg of either wild-type or
mtCXCL12. Furthermore, studies in vitro showed that
neither high doses of wild-type nor mtCXCL12 induced
an oxidative respiratory burst in blood-derived murine
leukocytes, promulgating the absence of a damaging
systemic inflammatory response in response to these
agents. The observed failure of CXCL12 to induce an
oxidative respiratory burst is consistent with results of a
previous study (37) and contrasts with the potential of
inflammatory chemokines such as CCL7 and CXCL8 to
induce such a burst (13, 38). The absence of apparent
toxicity of exogenous CXCL12 is compatible with the
expression of high levels of this chemokine within
many tissues under normal conditions, including the
brain, lungs, bone marrow, and liver (17).
Following demonstration of the safety of intravenous
administration of wild-type CXCL12 and mtCXCL12, a
series of experiments was performed to assess the
potential of both these chemokines to modulate the
infiltration by mononuclear leukocytes of CXCL12-
filled air pouches. Notably, it was found that intrave-
nous administration of wild-type CXCL12 enhanced
infiltration of the air pouches, while administration of
mtCXCL12 effectively prevented the recruitment of
mononuclear leukocytes to air pouches.
To examine a potential mechanism for the anti-
inflammatory activity of mtCXCL12, splenocytes were
isolated from animals 24 h after intravenous adminis-
tration of PBS, wild-type CXCL12, or mtCXCL12. It was
found that mononuclear splenocytes from animals that
had been treated with the non-HS-binding mtCXCL12
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showed both reduced expression of CXCR4 and che-
motaxis toward CXCL12. By contrast, splenocytes from
animals treated 24 h earlier with either PBS or wild-type
CXCL12 showed levels of CXCR4 expression that were
not significantly different. These data are consistent
with the reported kinetics of ligand-induced CXCR4
phosphorylation, followed by desensitization and inter-
nalization with a T-cell surface half-life of 5 min (39).
The transient availability of wild-type CXCL12 in the
blood will allow efficient CXCR4 recycling; indeed, it
has been reported that this process can be 75% com-
plete within 2 h (40).
In addition to down-regulation of CXCR4 expression
and desensitization of the chemotactic response toward
CXCL12, chronic exposure to CXCL12 was shown to
prevent the transient increase in adhesion to either
monomeric or oligomeric (antibody cross-linked) VCAM-1.
Fc fusion protein produced by treatment of VLA4-
expressing T cells with CXCL12. The changes in adhe-
sion observed using the 2 variants of this assay are
consistent with increased integrin affinity and avidity,
respectively (23). Notably, transient stimulation of T
cells with wild-type chemokine followed by a period of
rest allowed the cells to respond normally by transient
adhesion to VCAM-1 following secondary exposure to
CXCL12. Activation of the adhesive functions of the
a4b1 integrin VLA4 plays an important role in mediat-
ing the transition from normal leukocyte rolling to
static adhesion onto the apical surface of chemokine-
expressing endothelial cells. The transient nature of
adhesive activation and the potential for desensitization
of this process both suggest that efficient intravascular
adhesion of VLA-4-expressing cells can only occur when
both CXCL12 and VCAM-1 are encountered at the site
of leukocyte to endothelial cell contact (41). While this
is the case when wild-type chemokine is bound to HS
on the surface of VCAM-1-expressing endothelial cells,
the non-HS-binding mtCXCL12 has the potential to
trigger an inappropriate transient increase in adhesive
potential followed by desensitization of this process at a
site distant from the endothelial surface.
These data are consistent with a model in which
non-HS-biding mtCXCL12 persists in the circulation
and chronically stimulates CXCR4 in blood-borne leu-
kocytes, while wild-type CXCL12 is only present tran-
siently leading to equally transient chemokine receptor
stimulation. Previous studies (42) have demonstrated
internalization of CXCR4 following ligand binding.
The lower level of CXCR4 observed in leukocytes from
animals treated with mtCXCL12 suggests that this li-
gand maintains chronic receptor internalization in vivo.
This leads to receptor desensitization that can explain
the failure of leukocytes from these animals to respond
as efficiently as cells from animals treated with wild-type
CXCL12 in chemotaxis assays. Notably, chronic but
not transient stimulation of CXCR4 also resulted in
the failure of normal activation of the important
proadhesive integrin VLA-4 following restimulation
with CXCL12.
While this report demonstrates a potential to induce
homologous tolerance of wild-type CXCL12, the possi-
bility that a wider, heterologous GPCR tolerance is also
produced cannot be discounted. Such tolerance could
explain both the blockade of the chemotactic response
to synovial fluid from joints of patients with rheumatoid
arthritis and the reduction of background inflamma-
tion in PBS-filled air pouches produced by mtCXCL12.
Heterologous desensitization is a well-established fea-
ture of GPCRs (31) and has been proposed as an
explanation for anti-inflammatory activity of other non-
GAG-binding chemokines receptor agonists (5). The
potential of a non-HS-binding variant of the homeo-
static, non-respiratory-burst-inducing chemokine CXCL12
to induce such tolerance suggests that appropriate
CXCR4 agonists may be developed as powerful anti-
inflammatory agents.
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